Transfection of RNA encoding tumor antigens following maturation of dendritic cells and to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes

Molecular Therapy

Volumn 9, Issue 5, 2004, Pages 757-764

  Liao, Xinsheng ^a,c   Li, Yongqing ^a   Bonini, Chiara ^a,d   Nair, Smita ^b   Gilboa, Eli ^b   Greenberg, Philip D ^a   Yee, Cassian ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Adoptive therapy; Cytotoxic T lymphocytes; Dendritic cell; RNA transfection; Vaccine therapy

Indexed keywords

CANCER VACCINE; MESSENGER RNA; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL MATURATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DATA ANALYSIS; DENDRITIC CELL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; TUMOR CELL DESTRUCTION; VACCINATION;

EID: 2442680269     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.02.011     Document Type: Review

References (27)

1. Greenberg, P. D. (1991). Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281.
2. Pardoll, D. (2001). T cells and tumours. Nature 411: 1010.
3. Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature 392: 245.
4. Fong, L., and Engleman, E. G. (2000). Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18: 245.
5. Nestle, F. O., et al. (1998). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328.
6. Thurner, B., et al. (1999). Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190: 1669.
7. + cells. Hum. Gene Ther. 10: 175.
8. Strobel, I., Berchtold, S., Gotze, A., Schulze, U., Schuler, G., and Steinkasserer, A. (2000). Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 7: 2028.
9. Rosenberg, S. A. (2001). Progress in human tumour immunology and immunotherapy. Nature 411: 380.
10. Alexander-Miller, M. A., Leggatt, G. R., and Berzofsky, J. A. (1996). Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102.
11. Yee, C., Savage, P. A., Lee, P. P., Davis, M. M., and Greenberg, P. D. (1999). Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162: 2227.
12. Wang, R. F., and Wang, H. Y. (2002). Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol. 20: 149.
13. Riddell, S. R., et al. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients, Nat. Med. 2: 216.
14. Powell, S. K., et al. (1999). In vitro analysis of transformation potential associated with retroviral vector insertions. Hum. Gene Ther. 10: 2123.
15. Van Tendeloo, V. F., et al. (2001). Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98: 49.
16. Nair, S. K., Boczkowski, D., Morse, M., Cumming, R. I., Lyerly, H. K., and Gilboa, E. (1998). Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16: 364.
17. Dhodapkar, M. V., et al. (1999). Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104: 173.
18. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., and Bhardwaj, N. (2001). Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193: 233.
19. Kalady, M. F., Onaitis, M. W., Padilla, K. M., Emani, S., Tyler, D. S., and Pruitt, S. K. (2002). Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J. Surg. Res. 105: 17.
20. Morel, S., et al. (2000). Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12: 107.
21. Kawakami, Y., et al. (1994). Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91: 3515.
22. Coulie, P. G., et al. (1994). A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180: 35.
23. Heiser, A., et al. (2000). Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol. 164: 5508.
24. Mercado, R., Vijh, S., Allen, S. E., Kerksiek, K., Pilip, I. M., and Pamer, E. G. (2000). Early programming of T cell populations responding to bacterial infection. J. Immunol. 165: 6833.
25. Wherry, E. J., Puorro, K. A., Porgador, A., and Eisenlohr, L. C. (1999). The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163: 3735.
26. Badovinac, V. P., Porter, B. B., and Harty, J. T. (2002). Programmed contraction of CD8(+) T cells after infection. Nat. Immunol. 3: 619.
27. Kedl, R. M., et al. (2000). T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp, Med. 192: 1105.